1919868-75-9 Usage
Uses
Used in Pharmaceutical Research and Development:
3-nitropyrazolo[1,5-a]pyrimidin-5(4H)-one is utilized as a key intermediate in the synthesis of various pharmaceuticals due to its ability to be transformed into a variety of bioactive compounds. Its role in the creation of nitropyrazole derivatives is particularly noteworthy, as these compounds have shown potential in treating inflammatory conditions and cancer.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-nitropyrazolo[1,5-a]pyrimidin-5(4H)-one serves as an important subject for studying its reactivity and the mechanisms of its reactions. Understanding these aspects can lead to the design of new drugs with improved efficacy and selectivity.
Used in the Synthesis of Bioactive Compounds:
3-nitropyrazolo[1,5-a]pyrimidin-5(4H)-one is employed as a precursor in the synthesis of bioactive compounds, leveraging its chemical properties to create molecules with potential therapeutic applications. Its versatility in chemical reactions allows for the development of a diverse range of compounds with different biological activities.
Used in Anti-inflammatory and Anticancer Drug Development:
3-nitropyrazolo[1,5-a]pyrimidin-5(4H)-one is used as a starting material for the development of anti-inflammatory and anticancer drugs. The nitropyrazole derivatives derived from 3-nitropyrazolo[1,5-a]pyrimidin-5(4H)-one have shown promising results in inhibiting inflammation and tumor growth, making them valuable in the search for new therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1919868-75-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,9,1,9,8,6 and 8 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1919868-75:
(9*1)+(8*9)+(7*1)+(6*9)+(5*8)+(4*6)+(3*8)+(2*7)+(1*5)=249
249 % 10 = 9
So 1919868-75-9 is a valid CAS Registry Number.
1919868-75-9Relevant academic research and scientific papers
Preparation and application of protein receptor kinase inhibitor
-
Paragraph 0121-0122; 0135-0137, (2020/05/02)
The invention provides a preparation method of a protein receptor kinase inhibitor. Specifically, the invention discloses a compound as shown in a formula I or a stereoisomer or racemate or pharmaceutically acceptable salt thereof, and the definition of each group is as shown in the specification. The invention also discloses application of the compound as a TRK kinase inhibitor.
METHODS OF TREATING PEDIATRIC CANCERS
-
Paragraph 0408, (2017/10/18)
A method of treating a pediatric cancer in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrro
CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE
-
Paragraph 0239-0240, (2016/06/06)
A novel crystalline form of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form.
